| Primary information |
|---|
| sequence ID | Seq_5314 |
| Peptide sequence | MADEAGSEADHEGTHST |
| CancerPDF_ID | CancerPDF_ID1224, CancerPDF_ID1225, CancerPDF_ID2344, CancerPDF_ID2347, CancerPDF_ID9681, CancerPDF_ID9682, |
| PMID | 21136997,21136997,21136997,21136997,21533267,21533267 |
| Protein Name | Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Serum,Plasma,Plasma,Serum,Serum |
| M/Z | 1743.66422,1759.65914,1743.6642,1759.6591,582.23,587.56 |
| Charge | 1,1,1,1,3,3 |
| Mass (in Da) | NA,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC/MS/MS |
| Quantification Technique | LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,NA,NA,NA,1.49,1.49 |
| CancerPDF_ID | CancerPDF_ID1224, CancerPDF_ID1225, CancerPDF_ID2344, CancerPDF_ID2347, CancerPDF_ID9681, CancerPDF_ID9682, |
| p-Value | 5.64E-05,NA,NA,NA,NA,NA |
| Software | MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT |
| Length | 17,17,17,17,17,17 |
| Cancer Type | Colorectal cancer,Colorectal cancer,Normal,Normal,Lung adenocarcinoma,Lung adenocarcinoma |
| Database | SwissProt Database,SwissProt Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4),Swissprot Database (57.4) |
| Modification | NA,Oxidation of Met,NA,NA,NA,Oxidation |
| Number of Patients | 30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | Differentially expressed between cancer vs normal,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
| Sensitivity | 0.898,NA,NA,NA,NA,NA |
| Specificity | 0.946,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |